This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
$$2999
The global vaginitis therapeutics market size was valued at USD 3.2 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030. Increasing awareness among women about the importance of maintaining good vaginal health, the introduction of new drugs for the treatment of vaginitis, and the growing demand for improved healthcare infrastructure are some of the major factors driving the market.
In 2022, the anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9%, owing to the rising cases of bacterial vaginosis. The Centers for Disease Control and Prevention reported that around 21 million women between the ages of 14 to 49 suffered from this disease. Metronidazole, clindamycin, and tinidazole are used to treat bacterial vaginosis.
Some key companies are also developing and receiving approvals for improved treatment options to treat this condition. For instance, in July 2021, the Food and Drug Administration (FDA) approved Solosec (secnidazole) for treating trichomoniasis. Solosec was launched to treat bacterial vaginosis and is an anti-bacterial substance that enters the bacterial and trichomonas cells where the nitroreductase enzyme reduces the nitro group.
Some of the key participants involved in the global vaginitis therapeutics market include:
RELATED PRODUCTS
By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030
The bacterial vaginosis treatment market is segmented on the basis of treatment, dosage form, route of administration, distribution channel and end-user.